4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Septerna, Inc. (SEPN) operates in the Biotechnology industry and is headquartered in South San Francisco, United States with about 130 employees. Its market capitalization is roughly $2 billion. In the fiscal year ended 2025-12-31, SEPN reported $46M in revenue and ($49M) in net income.
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases.
Interactive charts & full statements → Open the SEPN valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Revenue | $46M | $1M | $0M | $0M |
| Operating Income (EBIT) | ($81M) | ($81M) | ($46M) | ($28M) |
| Net Income | ($49M) | ($72M) | $4M | ($28M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|
| Total Revenue | $26M | $24M | $22M | $0M | $0M |
| Operating Income (EBIT) | ($13M) | ($16M) | ($10M) | ($29M) | ($26M) |
| Net Income | ($9M) | ($11M) | $8M | ($25M) | ($22M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Assets | $596M | $457M | $131M | $36M |
| Total Liabilities | $214M | $36M | $169M | $80M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive SEPN viewer.
About TickerBase · Data methodology & sources